Authors :
Presenting Author: Charlotte Damien, MD – HUB Erasme
Nicolas Gaspard, MD, PhD – HUB Erasme
Rationale: Several prognosis factors of Status Epilepticus (SE) are well established, including refractoriness. Refractory SE is defined as persistent seizures despite appropriate use of two intravenous medications, one of which is a benzodiazepine. However, no data are available on the severity of refractoriness and its impact on prognosis.
Methods: A retrospective study was conducted including 381 SE, of which 172 refractory SE (RSE), as defined by ILAE.
The time of refractoriness was defined as the time of administration of third-line treatment. Hourly burden of ictal activities has been rated during the previous hour, on a clinical and/or EEG basis, when available. This burden was categorized in 4 categories: < 20%, 20 to 50 %, 50 to 99 % and 100%). Treatment administrated at refractoriness was also registered and categorized as continuous intravenous anesthetic drugs (CIVADs) and non-sedating antiepileptic drugs (AEDs).